132 related articles for article (PubMed ID: 4040729)
21. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
22. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
[TBL] [Abstract][Full Text] [Related]
23. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
24. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
25. Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.
Pelger RC; Lycklama A Nijeholt GA; Papapoulos SE; Hamdy NA
Bone; 2005 Jan; 36(1):1-5. PubMed ID: 15663996
[TBL] [Abstract][Full Text] [Related]
26. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
27. [Regression and disappearance of bone metastasis in a case of prostatic carcinoma after bilateral orchidectomy and oestrogen therapy (author's transl)].
Suhler A
J Urol (Paris); 1981; 87(4):227-9. PubMed ID: 7264352
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
[TBL] [Abstract][Full Text] [Related]
29. Metastases of prostate cancer express estrogen receptor-beta.
Lai JS; Brown LG; True LD; Hawley SJ; Etzioni RB; Higano CS; Ho SM; Vessella RL; Corey E
Urology; 2004 Oct; 64(4):814-20. PubMed ID: 15491740
[TBL] [Abstract][Full Text] [Related]
30. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract][Full Text] [Related]
32. Osteoblast function and osteomalacia in metastatic prostate cancer.
Clarke NW; McClure J; George NJ
Eur Urol; 1993; 24(2):286-90. PubMed ID: 8375452
[TBL] [Abstract][Full Text] [Related]
33. [Osteomalacia of mesenchymatous tumors. Apropos of a new case].
Lejeune E; Bouvier M; Meunier P; Vauzelle JL; Deplante JP; David L; Llorca G; André-Fouet E
Rev Rhum Mal Osteoartic; 1979 Mar; 46(3):187-93. PubMed ID: 472647
[No Abstract] [Full Text] [Related]
34. Oncogenic osteomalacia: lesion detection by MR skeletal survey.
Avila NA; Skarulis M; Rubino DM; Doppman JL
AJR Am J Roentgenol; 1996 Aug; 167(2):343-5. PubMed ID: 8686600
[No Abstract] [Full Text] [Related]
35. [Bone metastases diagnosed by ultrasound].
Stellamor K; Braun U; Urban M; Hruby W
Rontgenblatter; 1989 Feb; 42(2):73-6. PubMed ID: 2648552
[TBL] [Abstract][Full Text] [Related]
36. [Tumoral hypophosphoremic osteomalacia].
Koeger AC; Prier A; Vinceneux P; Camus JP
Presse Med; 1985 Oct; 14(33):1747-51. PubMed ID: 2933649
[TBL] [Abstract][Full Text] [Related]
37. Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
Vogelgesang SA; McMillin JM
J Urol; 1988 Nov; 140(5):1025-7. PubMed ID: 3172354
[TBL] [Abstract][Full Text] [Related]
38. [Bone lesions in a 59-year-old male].
Mariñosa M; Valderas G; Tapia G
Med Clin (Barc); 2003 Mar; 120(9):353-6. PubMed ID: 12646114
[No Abstract] [Full Text] [Related]
39. Painful but prolonged survival in man with 'bone metastases'.
Spahlinger D
Hosp Pract (Off Ed); 1984 Mar; 19(3):48C-48L, 48R. PubMed ID: 6421852
[No Abstract] [Full Text] [Related]
40. [Modification of bone metastases of prostatic carcinoma using estrogens. Roentgenological follow-up study].
Ludvik W; Riedl P; Zaunbauer W
Z Urol Nephrol; 1974 Mar; 67(3):165-9. PubMed ID: 4849197
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
